Because Helene Avraham-Katz has the BRCA2 mutation, certain chemotherapies work better and she is eligible for specific clinical trials.
Dr. Philip Philip focuses on disrupting cancer cell metabolism with devimistat, now in a phase III global clinical trial.
Dr. Kenneth Yu is testing a blood-based assay that looks at which types of chemotherapies will work best for each pancreatic cancer patient.
Dr. Andrea Califano leads a precision oncology clinical trial of the OncoTreat platform, which looks at proteins to determine treatment.
Dr. Noelle LoConte discusses a clinical trial for cancer patients, including pancreatic cancer patients, that have an NRG1 gene fusion.